- Conditions
- Hypertension
- Interventions
- valsartan + amlodipine
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 130
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Baltimore, Maryland + 3 more
- Conditions
- Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
- Interventions
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Drug
- Lead sponsor
- James A. Tumlin, MD
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Lawrenceville, Georgia • Bethlehem, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
- Interventions
- Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertension, Hypercholesterolemia, Dyslipidemia
- Interventions
- Valsartan and simvastatin
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
- Interventions
- Pharmacological Study, Romidepsin
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 11
- States / cities
- Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more
- Conditions
- End Stage Renal Disease
- Interventions
- Valine, EEA
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- simvastatin, Dapagliflozin, valsartan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Hypertension
- Interventions
- valsartan
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 265 participants
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- E.Hanover, New Jersey
- Conditions
- Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
- Interventions
- Valsartan 40 mg, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Post Acute Coronary Syndrome, Myocardial Ischemia
- Interventions
- Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Investigative Site, New Jersey
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- Pembrolizumab, Romidepsin
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Methamphetamine-dependence
- Interventions
- Magnetic resonance imaging (MRI), Methamphetamine Hydrochloride Tablets, Placebo oral tablet
- Behavioral · Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Romidepsin, Venetoclax
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Duarte, California • Omaha, Nebraska
- Conditions
- NAFLD
- Interventions
- AXA1957, AXA1125, Placebo
- Dietary Supplement
- Lead sponsor
- Axcella Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 18
- States / cities
- Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 14 more
- Conditions
- Salt-sensitive Hypertension
- Interventions
- Valsartan, LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Anaheim, California • Cypress, California • Glendale, California
- Conditions
- Eyelash Growth
- Interventions
- DIME Beauty Eyelash Boost Serum
- Other
- Lead sponsor
- Dime Beauty Co.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- acute resistance exercise with oral nutrition supplementation, stable tracer infusion
- Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 45 Years to 100 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Hypertension
- Interventions
- Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Philadelphia, Pennsylvania • Norfolk, Virginia
- Conditions
- Acute Myocardial Infarction
- Interventions
- LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
- Conditions
- Heart Failure
- Interventions
- LCZ696 (sacubitril/valsartan)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 66 more
- Conditions
- HYPERTENSION, HYPERCHOLESTEROLEMIA
- Interventions
- valsartan + simvastatin
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 369 participants
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Cerebrovascular Accident
- Interventions
- Valsartan
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Stroke, Acute
- Interventions
- Valsartan
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California